Shelton Capital Management’s Cytokinetics CYTK Stock Holding History

Shelton Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$345K	Hold	4,049	–	–	0.01%	490
2026 Q1	$267K	Hold	4,049	–	–	0.01%	553
2025 Q4	$257K	Buy	+4,049	New	+$252K	0.01%	554
2024 Q4	–	Sell	-3,995	Closed	-$211K	–	743
2024 Q3	$211K	Hold	3,995	–	–	0.01%	695
2024 Q2	$216K	Sell	3,995 -198	-5%	-$12K	0.01%	656
2024 Q1	$294K	Sell	4,193 -458	-10%	-$35.4K	0.01%	541
2023 Q4	$388K	Buy	+4,651	New	+$168K	0.01%	396
2023 Q1	–	Sell	-5,392	Closed	-$247K	–	741
2022 Q4	$247K	Hold	5,392	–	–	0.03%	531
2022 Q3	$261K	Hold	5,392	–	–	0.01%	504
2022 Q2	$212K	Buy	+5,392	New	+$217K	0.01%	647

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shelton Capital Management's CYTK Position: Q2 2026 in Review

Shelton Capital Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 4,049 shares worth $345K. The position accounts for 0.01% of the portfolio, ranked #490.

Shelton Capital Management first reported a position in CYTK in Q2 2022 and has held it in 10 quarters since. The position peaked at $388K in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Shelton Capital Management held 4,049 shares of Cytokinetics worth $345K as of Q2 2026.
Shelton Capital Management left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up 0.01% of Shelton Capital Management's portfolio in Q2 2026, its #490 holding.
Shelton Capital Management first reported a position in Cytokinetics in Q2 2022 and has held it in 10 quarters since.
Shelton Capital Management's Cytokinetics position peaked at $388K in Q4 2023.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.